Alzheimer's Disease (AD) is characterized by profound disturbances in RNA metabolism, which contribute to neurodegeneration through multiple interconnected mechanisms. RNA metabolism encompasses transcription, splicing, editing, nuclear export, trafficking, local translation, and decay—all processes that become dysfunctional in ADA et al. (2023). This page provides a comprehensive mechanistic overview of how RNA metabolism is disrupted in AD and how these defects contribute to disease progression.
The RNA metabolism dysregulation pathway in AD involves defects in mRNA translation and stability, non-coding RNA dysregulation, RNA splicing abnormalities, and stress granule formation. These disruptions are driven by amyloid-beta (Aβ) plaques, tau neurofibrillary tangles, and downstream signaling cascades that impair RNA-binding protein (RBP) functionD et al. (2024). Understanding these defects provides therapeutic targets for restoring RNA processing homeostasis in AD.
Translation initiation is a highly regulated process involving eukaryotic initiation factors (eIFs). In AD, multiple eIFs are dysregulated:
eIF2α phosphorylation: Stress-responsive eIF2α phosphorylation (via PERK kinase) globaly represses translation while selectively promoting expression of stress-response genesM et al. (2023). Chronic eIF2α phosphorylation in AD neurons impairs synaptic protein synthesis required for memory formation.
eIF4E/eIF4G dysregulation: The cap-binding protein eIF4E and its partner eIF4G are altered in AD, affecting the translation of mRNAs with complex 5' UTR structuresS et al. (2022). Proteins involved in synaptic function and neuronal connectivity are particularly affected.
mTOR pathway disruption: Hyperactive mTOR signaling in AD leads to aberrant translation regulation, with increased cap-dependent translation but impaired synaptic plasticity-related protein synthesisA et al. (2023).
mRNA stability is controlled by adenylate uridylate-rich elements (AREs) in 3' UTRs and associated RBPs:
Tristetraprolin (TTP): This ARE-binding protein that promotes mRNA decay is dysregulated in AD, leading to abnormal stabilization of inflammatory transcriptsT et al. (2022).
Hu proteins (HuR): The HuR RBP, which stabilizes many mRNAs, shows altered localization in AD, affecting the expression of key neuronal genesA et al. (2023).
MicroRNA-mediated decay: miRNAs such as miR-29 and miR-15 are altered in AD and contribute to mRNA destabilization of neuroprotective transcriptsC et al. (2022).
| mRNA | Change | Functional Consequence |
|---|---|---|
| BDNF | Decreased translation | Impaired synaptic plasticity |
| APP | Altered stability | Aβ production modulation |
| Tau (MAPT) | Increased translation | NFT formation |
| Synaptic proteins | Reduced synthesis | Synaptic dysfunction |
miRNAs are small non-coding RNAs that regulate gene expression post-transcriptionally. In AD, multiple miRNAs are dysregulated:
miR-9: One of the most consistently altered miRNAs in AD, miR-9 is involved in regulating:
miR-29 family: miR-29a/b are significantly reduced in AD brains and:
miR-146a: This inflammation-associated miRNA is increased in AD:
miR-34a: Elevated in AD, miR-34a:
lncRNAs are >200 nucleotide RNAs that regulate gene expression through multiple mechanisms:
NEAT1: This nuclear-enriched lncRNA:
MALAT1: Metastasis-associated lung adenocarcinoma transcript 1:
BACE1-AS: Antisense transcript of BACE1:
HAR1: Human accelerated region 1:
Pre-mRNA splicing is catalyzed by the spliceosome, and alternative splicing generates protein diversity. In AD:
Spliceosome components: Key splicing factors are altered:
Neuron-specific splicing: Genes with neuron-specific splicing patterns are affected:
Direct effects of Aβ on splicing machinery:
Tau pathology affects splicing:
| Gene | Splicing Change | Effect |
|---|---|---|
| APP | Altered exon 7/8 splicing | Affects Aβ production |
| Tau (MAPT) | 3R/4R ratio imbalance | NFT formation |
| BACE2 | Alternative splicing | Potential therapeutic target |
Neurons contain specialized RNA granules for transport and localization:
Dendritic RNA granules: Transport mRNAs to synapses:
Axonal RNA granules: Transport mRNAs in axons:
Stress granules (SGs): Form under stress:
Stress granule formation is a protective response that becomes pathological in AD:
Initiation factors sequestered:
RBP sequestration in AD:
SG Dynamics:
| Target | Strategy | Status |
|---|---|---|
| eIF2α phosphorylation | PERK inhibitors | Preclinical |
| SG disassembly | Small molecule modulators | Research |
| RBP function | Antisense oligonucleotides | Emerging |
Aβ directly and indirectly disrupts RNA processing:
Transcriptional effects:
RBP dysfunction:
miRNA dysregulation by Aβ:
Tau pathology impacts RNA processing at multiple levels:
Nuclear tau:
Cytoplasmic tau:
Tau post-translational modifications:
Aβ → RNA dysregulation → More Aβ:
Tau → RNA dysregulation → More tau:
eIF2α modulators:
mTOR inhibitors:
miRNA-based therapies:
lncRNA targeting:
Splice-switching oligonucleotides:
Small molecules:
SG modulators:
RNA-based biomarkers for AD:
| miRNA | Source | Change in AD | Utility |
|---|---|---|---|
| miR-9 | CSF | Decreased | Diagnostic |
| miR-29 | CSF | Decreased | Diagnostic |
| miR-146a | Brain | Increased | Progression |
| miR-34a | Blood | Increased | Diagnostic |
RNA metabolism dysregulation is a central feature of Alzheimer's Disease, affecting virtually every step of RNA processing from transcription to translation. Key findings include:
Therapeutic strategies targeting RNA metabolism hold promise for disease modification, though delivery and specificity remain significant challenges.